One year of SARS-CoV-2 evolution

Aiping Wu,Lulan Wang,Hang-Yu Zhou,Cheng-Yang Ji,Shang Zhou Xia,Yang Cao,Jing Meng,Xiao Ding,Sarah Gold,Taijiao Jiang,Genhong Cheng

DOI: https://doi.org/10.1016/j.chom.2021.02.017

2021-04-01

Abstract:Since the outbreak of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, the viral genome has acquired numerous mutations with the potential to increase transmission. One year after its emergence, we now further analyze emergent SARS-CoV-2 genome sequences in an effort to understand the evolution of this virus.

microbiology,virology,parasitology

What problem does this paper attempt to address?

The problem this paper attempts to address is the analysis of the evolution of the SARS-CoV-2 virus over the past year, particularly focusing on the mutations and deletions accumulated in its genome, and the impact of these changes on virus transmission, infectivity, and the efficacy of vaccines and monoclonal antibodies.

Specifically, the paper mainly explores the following aspects:

1. **Identification and analysis of mutations and deletions**: By comparing representative SARS-CoV-2 genome sequences, identifying the mutations and deletions accumulated over the past year, and analyzing the frequency and distribution of these changes.

2. **Epidemiological patterns of mutations**: Studying the distribution of these mutations over different times and regions to understand their transmission patterns and potential epidemiological impacts.

3. **Functional impact of key mutations**: Focusing particularly on key mutations in the S protein (such as D614G and N501Y), analyzing how these mutations affect the virus's ability to bind to the host receptor ACE2, thereby enhancing virus transmission and infectivity.

4. **Impact of mutations on vaccines and monoclonal antibodies**: Assessing whether these mutations affect the efficacy of existing vaccines and monoclonal antibodies, especially mutations in the RBD region on the action of neutralizing antibodies.

Through these analyses, the paper aims to provide scientific evidence for future epidemic prevention and vaccine development, helping to address the rapid evolution of the SARS-CoV-2 virus.